We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cognis Develops Two more Active Ingredients for Weight Management and Cognitive Performance from IMD

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cognis Develops Two more Active Ingredients for Weight Management and Cognitive Performance from IMD"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Specialty chemicals supplier Cognis and InterMed Discovery (IMD) are continuing their strategic cooperation: Cognis has now exclusively licensed two new active ingredients for weight management and cognitive performance from IMD, further expanding the company’s pipeline. Tests on the products Cognis has already acquired from IMD are already delivering promising results.

The sales potential is increasing for active ingredients in functional foods to support weight management and benefit heart and brain health, largely because obesity is becoming a major public health problem in many parts of the world and society as a whole is getting older.

During their ongoing collaboration, Cognis and IMD have utilized IMD’s database of biologically active natural substances and its IMD Bioprofiling® technology platform to discover functional ingredients for specific food applications, and to bring suitable active substances to market-readiness.

In combination with Cognis’ experience and expertise in nutrition, this has led to the discovery of additional product candidates that help with weight management and cognitive performance. Cognis’ own research has given it insights into important aspects of brain health such as learning ability, cognitive performance (and ways of maintaining this with age), alertness, and concentration.

One of the candidates is a new ingredient that is showing promising benefits for weight management in different test systems. The second new ingredient is a promising product for improving brain health, as in vivo tests have shown potential on cognitive performance. Cognis plans to carry out further in vivo tests and research studies for these ingredients later this year.

Cognis has already licensed four other ingredients from IMD targeting weight management and heart health. Clinical studies for one of these projects will already begin later this year. The other licensed ingredients are currently in advanced preclinical testing and scale-up process.

“Developing breakthrough innovations that are backed by strong science and deliver proven health benefits is a crucial part of our value-driven innovation strategy. We are following a holistic approach to create new concepts that meet consumer requirements. This generates added value for our customers allowing them to differentiate themselves from their competitors,” said Bernhard Mueller, Director Global R&D/Technology Cognis Nutrition & Health. “These latest ingredients will further strengthen our product portfolio in important global growth markets. We expect the first product to hit the market within the next years.”

Bernard Becker, Managing Director of InterMed Discovery added: “Such success bodes well for IMD’s future. It underlines the potential of IMD’s food ingredient pipeline and proves the strength of our technology platform. It furthermore confirms our business model to make natural products into an essential part of the life science and chemical industries of tomorrow.”

In March 2008, both companies announced a strategic cooperation. Under this agreement, Cognis can use IMD’s natural product database and has exclusive access to selected potential active ingredients for specific applications in functional foods and dietary supplements.